Company Overview of Theraclone Sciences, Inc.
Theraclone Sciences, Inc., a discovery-stage biotech company, develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. It provides In-Situ Therapeutic Antibody Rescue technology, which allows for the rapid testing of human antibodies to find those with exceptional biological functions and activities; and TCN-032, a recombinant human monoclonal antibody for the treatment of patients hospitalized with serious influenza. The company has antibody programs at preclinical and clinical development stage targeting serious medical conditions with a significant unmet medical need, including triple negative and endocrine treatment resistant HER-2 negative breast cancer...
1124 Columbia Street
Seattle Life Sciences Building
Seattle, WA 98104
Founded in 2004
Key Executives for Theraclone Sciences, Inc.
Chief Executive Officer and Director
Founder and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2016.
Theraclone Sciences, Inc. Key Developments
OncoResponse Will Use Theraclone's I-STAR Immune Repertoire Screening Technology
Oct 7 15
OncoResponse has been launched jointly by The University of Texas MD Anderson Cancer Center and Theraclone Sciences, of Seattle, Washington. OncoResponse will use Theraclone's I-STAR immune repertoire screening technology to identify therapeutic antibodies against novel targets from immuno-oncology treated patients. I-STAR technology rapidly screens antibodies made by the human immune system to identify those with exceptional reactivity that may lead to cancer treatment development.
Theraclone Sciences, Inc. Presents at BioPharm America 2015, Sep-15-2015 04:00 PM
Sep 12 15
Theraclone Sciences, Inc. Presents at BioPharm America 2015, Sep-15-2015 04:00 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Clifford J. Stocks, Chief Executive Officer and Director.
Wellcome Trust Selects Theraclone Sciences, Inc.'s I-STAR™ Technology to Identify Therapeutic Antibodies Against Ebola Virus
Apr 30 15
Theraclone Sciences, Inc. announced that its I-STAR™ Technology chosen by Wellcome Trust to identify Therapeutic Antibodies against Ebola Virus. The company will identify potential therapeutic antibodies against the Ebola virus utilizing the Company’s powerful human memory B-cell interrogation platform. The I-STARTM technology can rapidly screen antibodies from survivors of Ebola to uncover those with exceptional biologic activity that may lead to the development of a therapeutic antibody. BIO Ventures for Global Health was instrumental in forming a consortium of Ebola experts for the endeavor, and will collaborate with Theraclone on management of the project. To fund the initial screening and development efforts, Theraclone will receive up to $4.4 million in a Series C financing, which includes an investment from the Wellcome Trust along with existing investors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries